JDRF Reaches New Milestones in Work to Drive Cures for Type 1 Diabetes and Improve Lives
NEW YORK, Feb. 14, 2020 /PRNewswire/ -- JDRF, the leading global organization funding type 1 diabetes (T1D) research, funded $121.5 million directly and helped generate more than $400 million in total T1D research funds from nonprofits, government, and industry to propel a year of remarkable breakthroughs in 2019, JDRF announced today. JDRF research funding increased by 10 percent over the previous year.
“I am more excited about our progress than ever before, given the tremendous breakthroughs made in 2019,” said Aaron J. Kowalski, Ph.D., president and CEO of JDRF. “We could not be driving this work forward without the support of so many dedicated individuals, partners and organizations all helping us deliver on our mission to cure T1D and improve lives.”
JDRF funding supported more than 180 active T1D research grants and is funding about 70 clinical trials for drugs, biologic and devices to prevent or cure T1D. The organization also supported new investment through the JDRF T1D Fund in 15 T1D companies, including 11 focused on cures.
“We are focused on beta cell therapies and immune therapies to deliver cures for T1D,” Kowalski said. “At the same time, we continue accelerating work in glucose control and complication therapies to improve the lives of those living with type 1 diabetes today.”
Highlights of breakthroughs outlined in the 2019 Annual Report are:
Progress Toward Cures:
JDRF’s Annual Report also cites progress in advocacy and community engagement, two areas aimed at both supporting research and the T1D community. “The combined strengths of research, advocacy and community engagement are helping us support more members of the T1D community and enabling more people to support our mission,” Dr. Kowalski said. “JDRF works to build partnerships that advance research and build and sustain critical support for type 1 diabetes (T1D) research funded by the Federal Government.”
Expanding Access to Coverage:
Learn more about JDRF’s research and advocacy priorities at jdrf.org and read the health insurance guide JDRF has complied to help the T1D community navigate their healthcare and health insurance here.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact and uniting on a national stage to pool resources, passion and energy. We collaborate with academic institutions, policymakers and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.
View original content to download multimedia: http://www.prnewswire.com/news-releases/jdrf-reaches-new-milestones-in-work-to-drive-cures-for-type-1-diabetes-and-improve-lives-301005488.html